In a first-of-its-kind trial, researchers used tiny, simplified organs grown from patients’ cancer cells—so-called patient-derived organoids (PDOs)—to compare responses to anticancer agents in the laboratory and the clinic. The researchers focused on patients with chemotherapy-resistant metastatic gastrointestinal cancers. For these patients, targeted agents or novel investigational drugs can prolong survival, but in most cases no predictive biomarkers are available, so the process relies on trial and error.
Abbasi J. Patient-Derived Organoids Predict Cancer Treatment Response. JAMA. 2018;319(14):1427. doi:10.1001/jama.2018.3760
Customize your JAMA Network experience by selecting one or more topics from the list below.